Michael Steven Tung
Executive VP & CFODr. Michael Steven Tung, MD, MBA, serves as an Executive Vice President and Chief Financial Officer of vTv Therapeutics Inc. since May 19, 2025. Dr. Tung joined vTv Therapeutics with diversified finance, corporate strategy, investor relations and business development experience in the biopharmaceutical industry. He has financial management, investment experience and strategic leadership for both private and public companies in the life sciences industry. Prior to joining vTv Therapeutics, Dr. Tung most recently served as Chief Financial Officer of AdvanCell Pty Limited. He also held senior level positions in corporate strategy and investor relations at FibroGen Inc. and Aclaris Therapeutics. Earlier in his career, he led the portfolio construction and risk management of healthcare-dedicated funds as a Portfolio Manager at multiple firms. He served as Chief Financial Officer of AdvanCell Isotopes Pty Ltd. Dr. Tung served as Senior Vice President Corporate Strategy/Investor Relations at Aclaris Therapeutics, Inc. He served as Vice President of Investor Relations at Aclaris Therapeutics, Inc. Dr. Tung joined Aclaris Therapeutics, Inc. in 2013 covering stocks in the health care sector. He has been Principal and Senior Portfolio Manager of Turner Investments, Inc. since March 1, 2016. Dr. Tung has been a Global Equity Analyst at Turner Investments, LP since March 4, 2013 and serves as its Senior Portfolio Manager. Dr. Tung conducts fundamental analysis of companies in all capitalization ranges to generate investment ideas for the firm's growth, global/international and long/short separately managed accounts and mutual funds. He is a member of the firm's Health Care Team and follows companies in the biotechnology and pharmaceutical industries. Prior to this, Dr. Tung served as a Senior Analyst at Expo Capital Management, LLC. Dr. Tung joined Delaware Management Business in November 2006 and handled research and analysis and portfolio management in the healthcare sector for its emerging growth equity team. He served as Portfolio Manager of Turner Funds Turner Medical Sciences Long/Short Fund since March 4, 2013. He served as Portfolio Manager of Turner Funds Turner Titan Long/Short Fund. He served as a Vice President, Equity Analyst and Portfolio Manager at Delaware Management Business Trust (also known as Delaware Management Company, Inc.). He served as Vice President, Portfolio Manager and Equity Analyst various Delaware funds and its fund complex. Dr. Tung spent the prior 20 months as a Vice President at the Galleon Management, L.P., where he performed fundamental research in the medical technology and biotechnology sectors. From late 2003 to 2005, Dr. Tung was an Analyst responsible for investing in healthcare equities at Hambrecht & Quist Capital Management and he spent most of 2003 as a Junior Analyst at Durus Capital Management. He began his professional career in the medical field from 2001 to the beginning of 2003, first as a Physician at the Lemuel Shattuck Hospital of the Tufts University School of Medicine and then as an Anesthesiologist at Beth Israel Deaconess Medical Center at the Harvard Medical School. Dr. Tung is also a licensed Physician in the commonwealth of Massachusetts and New York. He completed the combined MD/MBA program at Tufts University School of Medicine and Brandeis University and received a Bachelor of Science degree in Biology and a Bachelor of Arts degree in Economics from George Washington University in 1997.
Positions
- Company NamevTv Therapeutics Inc.Stock CodeVTVTPositionExecutive VP & CFOColleagues
- PJPaul J. SekhriCEO, President & Chairman of the Board
- BKBarry K. BrownChief Accounting Officer
- CVCarmen ValcarceChief Scientific Officer & Executive VP
- EMElizabeth M. KeileyExecutive VP & General Counsel
- RSRichard S. NelsonExecutive VP of Corporate Development & Director
- RCRaymond CheongLead Independent Director
- AMAnne Michelle PhillipsIndependent Director
- DKDaniel K. SpiegelmanIndependent Director
